4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $28.70.

FDMT has been the topic of several recent analyst reports. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Barclays cut their target price on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Chardan Capital raised their price target on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $11.52 on Wednesday. The company has a market capitalization of $658.14 million, a PE ratio of -3.07 and a beta of 2.96. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $12.34. The company’s fifty day moving average price is $10.71 and its 200 day moving average price is $7.45.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. Analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the sale, the insider owned 3,594 shares in the company, valued at approximately $43,128. This trade represents a 42.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 10,763 shares of company stock valued at $109,415. Corporate insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BVF Inc. IL grew its stake in shares of 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock valued at $14,733,000 after purchasing an additional 1,890,647 shares during the period. Armistice Capital LLC grew its position in 4D Molecular Therapeutics by 265.3% in the third quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock valued at $9,524,000 after acquiring an additional 796,000 shares during the period. Federated Hermes Inc. grew its position in 4D Molecular Therapeutics by 33.4% in the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock valued at $6,186,000 after acquiring an additional 417,157 shares during the period. Acadian Asset Management LLC raised its stake in 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock worth $1,290,000 after acquiring an additional 367,317 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after acquiring an additional 213,264 shares during the period. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.